Association of Acute Kidney Injury Receiving Kidney Replacement Therapy With Prognosis of Critically Ill Patients With and Without Cancer: A Retrospective Study.


Journal

Critical care medicine
ISSN: 1530-0293
Titre abrégé: Crit Care Med
Pays: United States
ID NLM: 0355501

Informations de publication

Date de publication:
01 11 2021
Historique:
pubmed: 25 6 2021
medline: 19 11 2021
entrez: 24 6 2021
Statut: ppublish

Résumé

To assess outcomes of cancer patients receiving kidney replacement therapy due to acute kidney injury in ICUs and compare these with other patient groups receiving kidney replacement therapy in ICUs. Retrospective registry analysis. Prospectively collected database of 296,424 ICU patients. Patients with and without solid cancer with acute kidney injury necessitating kidney replacement therapy were identified and compared with those without acute kidney injury necessitating kidney replacement therapy. Descriptive statistics were used to ascertain prevalence of acute kidney injury necessitating kidney replacement therapy and solid cancer in ICU patients. Association of acute kidney injury necessitating kidney replacement therapy and cancer with prognosis was assessed using logistic regression analysis. To compare the attributable mortality of acute kidney injury necessitating kidney replacement therapy, 20,154 noncancer patients and 2,411 cancer patients without acute kidney injury necessitating kidney replacement therapy were matched with 12,827 noncancer patients and 1,079 cancer patients with acute kidney injury necessitating kidney replacement therapy. Thirty-five thousand three hundred fifty-six ICU patients (11.9%) had solid cancer. Acute kidney injury necessitating kidney replacement therapy was present in 1,408 (4.0%) cancer patients and 13,637 (5.2%) noncancer patients. Crude ICU and hospital mortality was higher in the cancer group (646 [45.9%] vs 4,674 [34.3%], p < 0.001, and 787 [55.9%] vs 5,935 [43.5%], p < 0.001). In multivariable logistic regression analyses, odds ratio (95% CI) for hospital mortality was 1.73 (1.62-1.85) for cancer compared with no cancer 3.57 (3.32-3.83) for acute kidney injury necessitating kidney replacement therapy and 1.07 (0.86-1.33) for their interaction. In the matched subcohort, attributable hospital mortality of acute kidney injury necessitating kidney replacement therapy was 56.7% in noncancer patients and 48.0% in cancer patients. Occurrence rate of acute kidney injury necessitating kidney replacement therapy and prognosis in ICU patients with solid cancer are comparable with other ICU patient groups. In cancer, acute kidney injury necessitating kidney replacement therapy is associated with higher crude hospital mortality. However, the specific attributable mortality conveyed by acute kidney injury necessitating kidney replacement therapy is actually lower in cancer patients than in noncancer patients. Diagnosis of cancer per se does not justify withholding kidney replacement therapy.

Identifiants

pubmed: 34166290
doi: 10.1097/CCM.0000000000005102
pii: 00003246-202111000-00010
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1932-1942

Informations de copyright

Copyright © 2021 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.

Déclaration de conflit d'intérêts

Mr. Fellinger and Dr. Posch’s institutions received funding from the Austrian Center for Documentation and Quality Assurance in Intensive Care Medicine. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Références

Azoulay E, Soares M, Darmon M, et al. Intensive care of the cancer patient: Recent achievements and remaining challenges. Ann Intensive Care. 2011; 1:5
Zampieri FG, Romano TG, Salluh JIF, et al. Trends in clinical profiles, organ support use and outcomes of patients with cancer requiring unplanned ICU admission: A multicenter cohort study. Intensive Care Med. 2021; 47:170–179
Díaz-Díaz D, Villanova Martínez M, Palencia Herrejón E. Oncological patients admitted to an intensive care unit. Analysis of predictors of in-hospital mortality. Med Intensiva. 2018; 42:346–353
Kingah P, Alzubaidi N, Yafawi JZD, et al. Factors associated with mortality in patients with a solid malignancy admitted to the intensive care unit—a prospective observational study. J Crit Care Med. 2018; 4:137–142
Darmon M, Bourmaud A, Georges Q, et al. Changes in critically ill cancer patients’ short-term outcome over the last decades: Results of systematic review with meta-analysis on individual data. Intensive Care Med. 2019; 45:977–987
Funk GC, Bauer P, Burghuber OC, et al. Prevalence and prognosis of COPD in critically ill patients between 1998 and 2008. Eur Respir J. 2013; 41:792–799
Taccone FS, Artigas AA, Sprung CL, et al. Characteristics and outcomes of cancer patients in European ICUs. Crit Care. 2009; 13:R15
Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: Severe exacerbations and mortality. Thorax. 2012; 67:957–963
de Vries VA, Müller MCA, Arbous MS, et al.; HEMA-ICU Study Group. Long-term outcome of patients with a hematologic malignancy and multiple organ failure admitted at the intensive care. Crit Care Med. 2019; 47:e120–e128
Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012; 380:756–766
Druml W. Systemic consequences of acute kidney injury. Curr Opin Crit Care. 2014; 20:613–619
Vaara ST, Pettilä V, Kaukonen KM, et al.; Finnish Acute Kidney Injury Study Group. The attributable mortality of acute kidney injury: A sequentially matched analysis*. Crit Care Med. 2014; 42:878–885
Metnitz PG, Krenn CG, Steltzer H, et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med. 2002; 30:2051–2058
Perazella MA, Rosner MH. Acute kidney injury in patients with cancer. Oncol Willist Park. 2018; 32:351–359
Lameire N, Vanholder R, Van Biesen W, et al. Acute kidney injury in critically ill cancer patients: An update. Crit Care. 2016; 20:209
Rosner MH, Perazella MA. Acute kidney injury in patients with cancer. N Engl J Med. 2017; 375:1770–1781
Christiansen CF, Johansen MB, Langeberg WJ, et al. Incidence of acute kidney injury in cancer patients: A Danish population-based cohort study. Eur J Intern Med. 2011; 22:399–406
Kemlin D, Biard L, Kerhuel L, et al. Acute kidney injury in critically ill patients with solid tumours. Nephrol Dial Transplant. 2018; 33:1997–2005
Lahoti A, Nates JL, Wakefield CD, et al. Costs and outcomes of acute kidney injury in critically ill patients with cancer. J Support Oncol. 2011; 9:149–155
Maccariello E, Valente C, Nogueira L, et al. Outcomes of cancer and non-cancer patients with acute kidney injury and need of renal replacement therapy admitted to general intensive care units. Nephrol Dial Transplant. 2011; 26:537–543
Seylanova N, Crichton S, Zhang J, et al. Acute kidney injury in critically ill cancer patients is associated with mortality: A retrospective analysis. PLoS One. 2020; 15:e0232370
Staufer K, Roedl K, Kivaranovic D, et al. Renal replacement therapy in critically ill liver cirrhotic patients-outcome and clinical implications. Liver Int. 2017; 37:843–850
Darmon M, Thiery G, Ciroldi M, et al. Should dialysis be offered to cancer patients with acute kidney injury? Intensive Care Med. 2007; 33:765–772
Moss AH. To dialyze or not: The patient with metastatic cancer and AKI in the intensive care unit. Clin J Am Soc Nephrol. 2012; 7:1507–1512
Metnitz PG, Steltzer H, Popow C, et al. [Definition and evaluation of a documentation standard for intensive care medicine: The ASDI (Working Group for Standardization of a documentation system for Intensive care medicine) pilot project]. Wien Klin Wochenschr. 1997; 109:132–138
Metnitz PG, Moreno RP, Almeida E, et al.; SAPS 3 Investigators. SAPS 3–from evaluation of the patient to evaluation of the intensive care unit. Part 1: Objectives, methods and cohort description. Intensive Care Med. 2005; 31:1336–1344
Miranda DR, de Rijk A, Schaufeli W. Simplified therapeutic intervention scoring system: The TISS-28 items–results from a multicenter study. Crit Care Med. 1996; 24:64–73
Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Inter Suppl. 2012; 2:1–138
Rosner MH, Perazella MA. Acute kidney injury in the patient with cancer. Kidney Res Clin Pract. 2019; 38:295–308
Wanchoo R, Stotter BR, Bayer RL, et al. Acute kidney injury in hematopoietic stem cell transplantation. Curr Opin Crit Care. 2019; 25:531–538
Renaghan AD, Jaimes EA, Malyszko J, et al. Acute kidney injury and CKD associated with hematopoietic stem cell transplantation. Clin J Am Soc Nephrol. 2020; 15:289–297
Wang LY, Wang JN, Diao ZL, et al. Acute kidney injury in oncology patients. J Cancer. 2020; 11:4700–4708
Gordon L, Dokouhaki P, Hagel K, et al. Acute kidney injury from immune checkpoint inhibitor use. BMJ Case Rep. 2019; 12:e231211
Meraz-Muñoz A, Amir E, Ng P, et al. Acute kidney injury associated with immune checkpoint inhibitor therapy: Incidence, risk factors and outcomes. J Immunother Cancer. 2020; 8:e000467
Kitchlu A, McArthur E, Amir E, et al. Acute kidney injury in patients receiving systemic treatment for cancer: A population-based cohort study. J Natl Cancer Inst. 2019; 111:727–736
Park SE, Hwang JH, Choi JH, et al. Incidence, risk factors, and clinical outcomes of acute kidney injury caused by palliative chemotherapy in lung cancer. J Cancer. 2019; 10:5332–5338
Hong SI, Ahn S, Lee YS, et al. Contrast-induced nephropathy in patients with active cancer undergoing contrast-enhanced computed tomography. Support Care Cancer. 2016; 24:1011–1017
Salahudeen AK, Doshi SM, Pawar T, et al. Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. Clin J Am Soc Nephrol. 2013; 8:347–354
Libório AB, Abreu KLS, Silva GB Jr, et al. Predicting hospital mortality in critically ill cancer patients according to acute kidney injury severity. Oncology. 2011; 80:160–166
Slagelse C, Gammelager H, Iversen LH, et al. Acute kidney injury and 1-year mortality after colorectal cancer surgery: A population-based cohort study. BMJ Open. 2019; 9:e024817
Praça APA, Nassar AP Jr, Caruso P. Outcomes of cancer patients discharged from ICU after a decision to forgo life-sustaining therapies. Crit Care Med. 2019; 47:e454–e460
Péron J, Neven A, Collette L, et al. Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: A pooled analysis of European Organisation for Research and Treatment of Cancer trials. Nephrol Dial Transplant. 2020;gfaa049
Brunet F, Lanore JJ, Dhainaut JF, et al. Is intensive care justified for patients with haematological malignancies? Intensive Care Med. 1990; 16:291–297
Malyszko J, Tesarova P, Capasso G, et al. The link between kidney disease and cancer: Complications and treatment. Lancet. 2020; 396:277–287
Rhodes A, Ferdinande P, Flaatten H, et al. The variability of critical care bed numbers in Europe. Intensive Care Med. 2012; 38:1647–1653

Auteurs

Wilfred Druml (W)

Department of Medicine III, Division of Nephrology, Medical University of Vienna, Vienna, Austria.

Paul Zajic (P)

Division of General Anaesthesiology, Emergency and Intensive Care Medicine, Medical University of Graz, Graz, Austria.

Peter Schellongowski (P)

Department of Medicine I, Intensive Care Unit, Medical University of Vienna, Vienna, Austria.

Tobias Fellinger (T)

Austrian Center for Documentation and Quality Assurance in Intensive Care (ASDI), Vienna, Austria.
Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.

Barbara Metnitz (B)

Austrian Center for Documentation and Quality Assurance in Intensive Care (ASDI), Vienna, Austria.

Martin Posch (M)

Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.

Philipp G H Metnitz (PGH)

Division of General Anaesthesiology, Emergency and Intensive Care Medicine, Medical University of Graz, Graz, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH